### Ethambutol + isoniazid + pyrazinamide + rifampicin

**Indication**
- Tuberculosis

**INN**
- Ethambutol + isoniazid + pyrazinamide + rifampicin

**Medicine type**
- Chemical agent

**List type**
- Core

**Additional notes**
- WHO recommends and endorses the use of fixed-dose combinations and the development of appropriate new fixed-dose combinations, including modified dosage forms, non-refrigerated products and paediatric dosage forms of assured pharmaceutical quality.

**Formulations**
- Oral > Solid: 275 mg + 75 mg + 400 mg + 150 mg tablet

**EML status history**
- First added in 1999 ([TRS 895](#))
- Changed in 2007 ([TRS 950](#))

**Sex**
- All

**Age**
- Adolescents and adults

**Therapeutic alternatives**
- The recommendation is for this specific medicine

**Patent information**
- Patents have expired in most jurisdictions
- [Read more about patents.](#)

**Wikipedia**
- Ethambutol + isoniazid + pyrazinamide + rifampicin

**DrugBank**
- Ethambutol, Isoniazid, Pyrazinamide, Rifampicin

---

### Summary of evidence and Expert Committee recommendations

The EMLc Subcommittee did not endorse the inclusion of this fixed-dose combination for the treatment of tuberculosis on the EMLc. The various fixed-dose combinations were considered as a group, as there is no clinical evidence for any of these combinations in children. However, it is difficult to determine the necessary appropriate combinations and what the strengths of the components should be in FDCs for use in children without examining further data (including pharmacokinetic data, stratified by weight and age). The Subcommittee therefore decided to endorse the lower strength rifampicin + isoniazid combinations (60 mg + 30 mg and 60 mg + 60 mg) and rifampicin + isoniazid + pyrazinamide (60 mg + 30 mg + 150 mg) as probably useful for many children, but requested an urgent review of all clinical evidence to support these and other potential combinations.